Q) WHich is not a risk factor for malignancy in inflammatory bowel disease?
a) >50% crohn disease in colon
b) PSC
c) Old age of onset
d) use of Infliximab
Category: Rectum
Steroid Refractory Ulcerative colitis
Q) Not used in steroid refractory severe Ulcerative Colitis ( AIIMS 2020 Nov)
a) Infliximab
b) Azathioprine
c) Cyclosporine
d) Surgery
Bleeding in Ulcerative colitis
Q) 30 yr old female with severe rectal bleed known case of UC , on admission not responding to steroids and medical treatment .. next line of treatment ?
a) Subtotal colectomy with Ilerorectal anastomosis
b) Subtotal colectomy with ileostomy
c) Total Proctocolectomy TPC with ipaa
d) Tpc with end iliostomy
Histology of Crohn disease
Q) WHich of the following is not a histological feature of Crohn disease of the bowel
a) Stricture
b) Granuloma
c) Crypt Abscess
d) Goblet cell atrophy
Ca Rectum
Q) CA rectum 5 cm from anal verge which is T1N0 on evaluation. which of the following cannot be done for the treatment of the patient
A. Inter sphincteric resesction
B. APR
C. Transanal endoscopic resection
D. LAR
Total Mesorectal Excision
Q) Which of the following is not true about TME ( total mesorectal excision)
a. For all rectal cancer
b. For all even after NACRT
c. Less Neuro injury vs conventional dissection
d) Less recurrence
Another question on complete Mesorectal excision
Rectal Intussusception
Q) Pick the true statement about rectal intussusception
a) It is a rare finding in defecography
b) When found, it is found to be a common cause of refractory constipation
c) Biofeedback therapy and fibre intake is the mainstream treatment of choice
d) Rectopexy has had good long term results
Genetics ca rectum
Q) Good prognosis seen in – ca rectum.
A) MSI-H
B) MSI-L
C) BRAF
D) KRAS
Neoadjuvant Response in Rectal cancer
Q) In Regression of tumour after Neoadjuvant CTRT for rectal cancer are all except
A) Decrease in size
B) Nodal regression
C) Mucosal venous invasion in mri
D) Depth change
